Equities Analysts Set Expectations for Jounce Therapeutics,

Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) – Research analysts at Piper Sandler cut their FY2022 earnings per share estimates for Jounce Therapeutics in a research note issued on Wednesday, March 2nd. Piper Sandler analyst E. Tenthoff now anticipates that the company will earn ($2.63) per share for the year, down from their prior estimate […]

Related Keywords

Ohio , United States , Elizabeth Trehu , Piper Sandler , Colony Group , Stifel Financial Corp , Zacks Investment Research , Deutsche Bank , Macrophage Program , Nasdaq , Jounce Therapeutics Company Profile Get Rating , Jounce Therapeutics Inc , Jounce Therapeutics , Get Rating , Investment Research , Employees Retirement System , Therapeutics Company Profile , Lead Macrophage Program , Macrophage Targeting , Nasdaq Jnce , Jnce , Medical , Earnings Estimates ,